Prostate-Specific Membrane Antigen-Based Therapeutics
Author Information
Author(s): Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, Scott T. Tagawa
Primary Institution: Weill Cornell Medical College
Hypothesis
Can targeting prostate-specific membrane antigen (PSMA) improve therapeutic outcomes in prostate cancer?
Conclusion
PSMA-targeted therapies, including radioimmunotherapy and antibody-drug conjugates, show promise in treating prostate cancer with manageable toxicity.
Supporting Evidence
- PSMA is highly overexpressed in prostate cancer, making it an ideal target for therapy.
- Radiolabeled J591 demonstrated accurate tumor targeting and preliminary evidence of antitumor activity.
- Fractionated dosing of 177Lu-J591 allows for higher cumulative doses with less toxicity.
Takeaway
Doctors are trying to use a special protein found in prostate cancer cells to help treat the disease better and with fewer side effects.
Methodology
The study reviews various therapeutic approaches targeting PSMA, including radioimmunotherapy and antibody-drug conjugates, and discusses their clinical trials.
Limitations
The study acknowledges limitations in the effectiveness of current therapies and the challenges in patient selection for targeted treatments.
Participant Demographics
The majority of participants were men with progressive metastatic castration-resistant prostate cancer, median age 72 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website